<?xml version='1.0' encoding='utf-8'?>
<document id="25245190"><sentence text="Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy."><entity charOffset="22-35" id="DDI-PubMed.25245190.s1.e0" text="norethindrone" /><entity charOffset="63-72" id="DDI-PubMed.25245190.s1.e1" text="ritonavir" /><entity charOffset="81-91" id="DDI-PubMed.25245190.s1.e2" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.25245190.s1.e0" e2="DDI-PubMed.25245190.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25245190.s1.e0" e2="DDI-PubMed.25245190.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s1.e0" e2="DDI-PubMed.25245190.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s1.e1" e2="DDI-PubMed.25245190.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s1.e1" e2="DDI-PubMed.25245190.s1.e2" /></sentence><sentence text="Pharmacokinetics of norethindrone in combination oral contraceptive regimen are well described among HIV+ women treated with ritonavir-boosted protease inhibitor therapies; however, such characterization is lacking in women using progestin-only contraception"><entity charOffset="20-33" id="DDI-PubMed.25245190.s2.e0" text="norethindrone" /><entity charOffset="125-134" id="DDI-PubMed.25245190.s2.e1" text="ritonavir" /><entity charOffset="230-239" id="DDI-PubMed.25245190.s2.e2" text="progestin" /><pair ddi="false" e1="DDI-PubMed.25245190.s2.e0" e2="DDI-PubMed.25245190.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25245190.s2.e0" e2="DDI-PubMed.25245190.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s2.e0" e2="DDI-PubMed.25245190.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s2.e1" e2="DDI-PubMed.25245190.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s2.e1" e2="DDI-PubMed.25245190.s2.e2" /></sentence><sentence text=" Our objective is to characterize pharmacokinetics of norethindrone in HIV+ women using ritonavir-boosted atazanavir treatment during progestin-only contraceptive regimens"><entity charOffset="54-67" id="DDI-PubMed.25245190.s3.e0" text="norethindrone" /><entity charOffset="88-97" id="DDI-PubMed.25245190.s3.e1" text="ritonavir" /><entity charOffset="106-116" id="DDI-PubMed.25245190.s3.e2" text="atazanavir" /><entity charOffset="134-143" id="DDI-PubMed.25245190.s3.e3" text="progestin" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e0" e2="DDI-PubMed.25245190.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e0" e2="DDI-PubMed.25245190.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e0" e2="DDI-PubMed.25245190.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e0" e2="DDI-PubMed.25245190.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e1" e2="DDI-PubMed.25245190.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e1" e2="DDI-PubMed.25245190.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e1" e2="DDI-PubMed.25245190.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e2" e2="DDI-PubMed.25245190.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s3.e2" e2="DDI-PubMed.25245190.s3.e3" /></sentence><sentence text="" /><sentence text="An open-label, prospective, nonrandomized trial to characterize the pharmacokinetics of norethindrone in HIV+ women receiving ritonavir-boosted atazanavir (n=10; treatment group) and other antiretroviral therapy known to not alter norethindrone levels (n=17; control group) was conducted"><entity charOffset="88-101" id="DDI-PubMed.25245190.s5.e0" text="norethindrone" /><entity charOffset="126-135" id="DDI-PubMed.25245190.s5.e1" text="ritonavir" /><entity charOffset="144-154" id="DDI-PubMed.25245190.s5.e2" text="atazanavir" /><entity charOffset="231-244" id="DDI-PubMed.25245190.s5.e3" text="norethindrone" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e0" e2="DDI-PubMed.25245190.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e0" e2="DDI-PubMed.25245190.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e0" e2="DDI-PubMed.25245190.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e0" e2="DDI-PubMed.25245190.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e1" e2="DDI-PubMed.25245190.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e1" e2="DDI-PubMed.25245190.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e1" e2="DDI-PubMed.25245190.s5.e3" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e2" e2="DDI-PubMed.25245190.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s5.e2" e2="DDI-PubMed.25245190.s5.e3" /></sentence><sentence text=" Following informed consent, women were instructed to take a single daily fixed oral dose of 0" /><sentence text="35 mg norethindrone and 300 mg/100 mg atazanavir/ritonavir for 22 days"><entity charOffset="6-19" id="DDI-PubMed.25245190.s7.e0" text="norethindrone" /><entity charOffset="38-48" id="DDI-PubMed.25245190.s7.e1" text="atazanavir" /><entity charOffset="49-58" id="DDI-PubMed.25245190.s7.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25245190.s7.e0" e2="DDI-PubMed.25245190.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25245190.s7.e0" e2="DDI-PubMed.25245190.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s7.e0" e2="DDI-PubMed.25245190.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s7.e1" e2="DDI-PubMed.25245190.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s7.e1" e2="DDI-PubMed.25245190.s7.e2" /></sentence><sentence text=" On day 22, serial blood samples were collected by venous catheter at 0, 1, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h" /><sentence text=" Whole blood was processed to collect serum and stored at -20°C until later analysis using radioimmunoassay" /><sentence text=" Pharmacokinetic parameters were estimated using noncompartmental method" /><sentence text="" /><sentence text="In the treatment group, compared to the control group, an increase in area under the curve₀₋₂₄ (16" /><sentence text="69 h*ng/mL vs" /><sentence text=" 25" /><sentence text="20 h*ng/mL; p&lt;" /><sentence text="05) and maximum serum concentration (2" /><sentence text="09 ng/mL vs" /><sentence text=" 3" /><sentence text="19 ng/mL; p&lt;" /><sentence text="05), decrease (25%-40%) in apparent volume of distribution and apparent clearance, and unaltered half-life were observed" /><sentence text="" /><sentence text="Our findings suggest that progestin-only contraceptives, unlike combination oral contraceptives, benefit from drug-drug interaction and achieve higher levels of exposure"><entity charOffset="26-35" id="DDI-PubMed.25245190.s22.e0" text="progestin" /></sentence><sentence text=" Further studies are needed to establish whether pharmacokinetic interaction leads to favorable clinical outcomes" /><sentence text="" /><sentence text="Norethindrone-based progestin-only contraceptives, unlike combination oral contraceptives, exhibit greater drug exposure when co-administered with ritonavir-boosted atazanavir regimen and thus may not warrant a category 3 designation by the World Health Organization"><entity charOffset="0-13" id="DDI-PubMed.25245190.s25.e0" text="Norethindrone" /><entity charOffset="20-29" id="DDI-PubMed.25245190.s25.e1" text="progestin" /><entity charOffset="147-156" id="DDI-PubMed.25245190.s25.e2" text="ritonavir" /><entity charOffset="165-175" id="DDI-PubMed.25245190.s25.e3" text="atazanavir" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e0" e2="DDI-PubMed.25245190.s25.e0" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e0" e2="DDI-PubMed.25245190.s25.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e0" e2="DDI-PubMed.25245190.s25.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e0" e2="DDI-PubMed.25245190.s25.e3" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e1" e2="DDI-PubMed.25245190.s25.e1" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e1" e2="DDI-PubMed.25245190.s25.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e1" e2="DDI-PubMed.25245190.s25.e3" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e2" e2="DDI-PubMed.25245190.s25.e2" /><pair ddi="false" e1="DDI-PubMed.25245190.s25.e2" e2="DDI-PubMed.25245190.s25.e3" /></sentence><sentence text=" Prospective studies are needed to confirm whether pharmacokinetic interaction results in favorable clinical outcomes" /><sentence text="" /></document>